Drug Target and Biomarker: VEGFA (G7422)

NCBI ID: G7422

VEGFA

Drug Target and Biomarker: VEGFA

VEGFA plays a crucial role in angiogenesis and lymphangiogenesis, driving the growth of new blood vessels and lymphatic vessels.
The VEGF signaling pathway, along with other growth factors and factors like fibroblast growth factor (FGF) and angiopoietin-1 (Ang-1), regulates the sprouting of new blood vessels.
Feedback mechanisms involving locally concentrated signaling molecules, such as VEGF and angiopoietins, may contribute to the downregulation of gene expression involved in angiogenesis.
High molecular weight fucoidan, a hypothetical anti-angiogenic molecule, may inhibit VEGF and angiopoietin activity, preventing angiogenesis.
VEGFA can be regulated by various signaling pathways, including the STAT3 pathway and HIF1alpha, under both hypoxic and non-hypoxic conditions.
The dysregulation of VEGFA release and angiogenesis can occur under pathological conditions, such as in the tumor microenvironment, leading to the formation of poorly developed and leaky blood vessels.
VEGFAx, an antiangiogenic isoform of VEGFA, is released by endothelial cells in healthy tissues to prevent unwanted angiogenesis. However, in cancerous tissues, tumor cells can block or override its antiangiogenic activity, inducing angiogenesis.
The VEGF signaling pathway is connected to several biological mechanisms, including G protein-coupled receptors, MAPK cascade, cAMP/cGMP signaling, lipid metabolism, blood circulation, ion channel activity, and cellular response pathways.

Please note that the viewpoints presented above are derived solely from the given context and may not represent all possible perspectives on VEGFA.
Based on the given context information, here are some comprehensive summaries of different viewpoints related to Vascular Endothelial Growth Factor A (VEGFA):

VEGF-A can act through paracrine mechanisms, where it is synthesized and secreted by signal-sending cells to interact with distant cells through various receptors.
VEGF-A can also act in an autocrine manner, controlling cellular responses by binding to receptors within the same cell that produced it.
There is emerging evidence suggesting that VEGF-A can signal in an intracrine manner, either through interactions with receptors located within the cell, relocalization to the nucleus, or through other yet-to-be-characterized mechanisms.
VEGF plays a role in angiogenesis and placental growth, and its molecular mechanisms involve interactions with VEGF receptors and placental growth factor.
VEGF-A is involved in the transformation of mesenchymal stem cells into KS-like spindle-shaped cells, leading to endothelial lineage differentiation and the acquisition of tumorigenic features.
VEGF signaling is one of the major oncogenic signaling cascades and involves the binding of VEGF ligands to VEGF receptors, activating downstream pathways involved in angiogenesis.
Androgen regulation of VEGF transcription in prostate cancer involves the androgen receptor complexed with Sp1, binding to the core promoter region of the VEGF gene.

Protein Name: Vascular Endothelial Growth Factor A

Functions: Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth. Binding to NRP1 receptor initiates a signaling pathway needed for motor neuron axon guidance and cell body migration, including for the caudal migration of facial motor neurons from rhombomere 4 to rhombomere 6 during embryonic development (By similarity). Also binds the DEAR/FBXW7-AS1 receptor (PubMed:17446437)

The "VEGFA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about VEGFA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets